Skip to Content

Eovist Approval History

  • FDA approved: Yes (First approved July 3rd, 2008)
  • Brand name: Eovist
  • Generic name: gadoxetate disodium
  • Company: Bayer HealthCare Pharmaceuticals Inc.
  • Treatment for: Diagnosis and Investigation

Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Development History and FDA Approval Process for Eovist

Jul  8, 2008Approval FDA Approves Eovist to Detect and Characterize Focal Liver Lesions

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.